Author: Aldunate, Fabián; Echeverría, Natalia; Chiodi, Daniela; López, Pablo; Sánchez-Cicerón, Adriana; Fajardo, Alvaro; Soñora, Martín; Cristina, Juan; Hernández, Nelia; Moreno, Pilar
Title: Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients Document date: 2018_8_14
ID: 0avsdbnb_1
Snippet: Hepatitis C Virus (HCV) infection treatment has dramatically improved thanks to the introduction of direct-acting antiviral agents (DAAs). These antivirals have significantly increased response rates (up to 98%) and greatly reduced treatment duration [1] . Currently available DAAs are classified into four categories given their molecular targets in the HCV replication cycle: (1) NS3/4A protease inhibitors (PIs) bind to the active site of the NS3/.....
Document: Hepatitis C Virus (HCV) infection treatment has dramatically improved thanks to the introduction of direct-acting antiviral agents (DAAs). These antivirals have significantly increased response rates (up to 98%) and greatly reduced treatment duration [1] . Currently available DAAs are classified into four categories given their molecular targets in the HCV replication cycle: (1) NS3/4A protease inhibitors (PIs) bind to the active site of the NS3/4A protease; (2) NS5A inhibitors interact with domain 1 of the NS5A dimer, although the exact mechanism of NS5A inhibition remains to be fully elucidated; (3) nucleos(t)ide analog NS5B polymerase inhibitors are incorporated into the nascent RNA chain resulting in chain termination by compromising the binding of the incoming nucleotide; (4) nonnucleoside NS5B polymerase inhibitors interact with either the thumb 1, thumb 2, palm 1, or palm 2 domain of NS5B and inhibit polymerase activity by allosteric mechanisms [2] [3] [4] . However, the extreme mutation and high replication rates of HCV, together with the immune system pressure, lead to a remarkable genetic variability that can compromise the high response rates to DAAs due to the preexistence of resistanceassociated substitutions (RASs) [5, 6] .
Search related documents:
Co phrase search for related documents- molecular target and protease active site: 1, 2, 3, 4
- molecular target and protease inhibitor: 1, 2, 3, 4, 5, 6
- molecular target and replication cycle: 1, 2, 3
- molecular target and response rate: 1
- molecular target and treatment duration: 1
- polymerase activity and protease active site: 1
- polymerase activity and protease inhibitor: 1, 2, 3, 4
- polymerase activity and replication cycle: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- polymerase activity and replication rate: 1, 2
- polymerase activity and treatment duration: 1, 2
- protease active site and replication cycle: 1, 2
- protease active site and system pressure: 1
- protease inhibitor and replication cycle: 1, 2, 3, 4, 5
- protease inhibitor and treatment duration: 1, 2, 3
- response rate and significantly response rate increase: 1
- response rate and system pressure: 1, 2
- response rate and treatment duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- response rate increase and significantly response rate increase: 1
- system pressure and treatment duration: 1
Co phrase search for related documents, hyperlinks ordered by date